Anxiety treatment of methamphetamine‑dependent patients with buprenorphine: A randomized, double‑blind, clinical trial

Tzu Chi Medical Journal

article

Jamshid Ahmadi¹  Amir Bazrafshan¹  Ali Sahraian²  Sara Jalali¹  Maedeh Fakhermanesh¹  Zahra Hooshyari³ 

[1] Substance Abuse Research Center, Shiraz University of Medical Sciences;Research Center of Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences;Psychiatry and Psychology Research Center, Tehran University of Medical Science;Virtual School of Medical Education and Management, Shahid Beheshti University of Medical Sciences

关键词: Anxiety;    Buprenorphine;    Methamphetamine;    Substance use disorderspsychotic;   

DOI  :  10.4103/tcmj.tcmj_297_21

来源: Wolters Kluwer Medknow Publications

【 摘 要 】

Objectives: In this double‑blind, randomized clinical trial, the effectiveness of buprenorphine (BUPRE) in the reduction of anxiety symptoms among the methamphetamine (MA) dependents was evaluated. Materials and Methods: The 60 MA‑dependent patients were randomly assigned to three groups (0.1 mg, 1 mg, and 8 mg of BUPRE), The Hamilton Anxiety Rating Scale was administrated to assess the anxiety symptoms daily at baseline and second to the 5th day after intervention. The inclusion criteria were the MA dependence, age of over 18 years, and absence of any chronic physical illnesses; exclusion criteria were the presence of other drug dependence in combination with MA. The mixed‑design analysis of variance was performed for data analysis. Results: A significant main effect of time (F = 51.456, P < 0.001) and group (F = 4.572, P = 0.014) and group‑by‑time interaction (F = 8.475, P < 0.001) were detected. Conclusions: This finding supports the efficacy of BUPRE to decrease anxiety. High doses of the drug (1 and 8 mg) were more effective than 0.1 mg. Here was not a significant difference between anxiety score when patients received 1 mg of BUPRE instead of 8 mg.

【 授权许可】

Unknown